1Inoue R, Natazuka T, Shimoyama M, et al. Feasibility of high-dose chemotherapy without stem cell support as a firstline treatment for non-HodgkinXs aggressive lymphoma: a pilot study[J]. Leuk Lymphoma, 2000, 36(3-4) : 315.
6Goss P E, Shepherd F. Dexamethasone/etoposlde/ifos- famide/cisplatin(DICE) as therapy for patient with advanced refractorynon- HodgkinXs lymphoma; preliminary report of phase Ⅱ study[J]. Ann Oncol, 1991, 2(11): 43.
7孙燕,周际昌.临床肿瘤内科手册[M].第3版.北京:人民卫生出版社,1996.342.
8Haim N, Ben-Shahar M. Dexsmethasone, etoposide, ifosfamide and cisplatin as second-line therapy in patients with aggressivenon-HodgkinXs lyrnphoma[J ]. Cancer, 1997, 80 (10) : 1989.
5Fisher RI , Gaynor ER , Dahlberg S , et al . Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins[J] . N Engl J Med, 1993, 328(2):1002-1006.
6Rule S, Tighe M , Davies S, et al. Vinorelbine in the treatment of lymphoma[J]. Hematol Oncol , 1998,16(3) :101-105.
7Yamazaki T, Kura Y, Sawada U. Treatment of intermddiate and high grade non-Hodgkin's lymphoma[J]. Nippon Rinsho, 2000, 58(3): 695-698.
8Plantier C I, Dupriez B, Simon M, et al. The VIM3-Ara-C regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hoghkin's lymphomas[J]. Leukemia, 1999, 13 (2): 282-288.
9Sarris A H, Romaguera J, Hagemeister F B, et al. Ifinotecan in relapsed or refractory non-Hodgkin's lymphoma [J]. Oncology (Huntingt), 2001,15(7 Suppl 8): 53-56.
10Kraut E H, Balcerzak S P, Young D, et al. A phase Ⅱ study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase Ⅱ research consortium study[J]. Cancer Invest, 2002, 20(2): 174-179.
